Language:

Visual Outcomes Following Intravitreal Ranibizumab for Diabetic Macular Edema in a Pro Re Nata Protocol from Baseline: A Real-World Experience

Asia-Pacific journal of ophthalmology (Philadelphia, Pa.), 2019-05, Vol.8 (3), p.200 [Peer Reviewed Journal]

Copyright 2019 Asia-Pacific Academy of Ophthalmology. ;ISSN: 2162-0989 ;EISSN: 2162-0989 ;DOI: 10.22608/apo.2018413 ;PMID: 31165603

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
Visual Outcomes Following Intravitreal Ranibizumab for Diabetic Macular Edema in a Pro Re Nata Protocol from Baseline: A Real-World Experience
Author: James, Datta G P ; Mitkute, Doville ; Porter, Grazyna ; Vayalambrone, Deepak
Subjects: Adult ; Aged ; Aged, 80 and over ; Angiogenesis Inhibitors - administration & dosage ; Diabetic Retinopathy - complications ; Diabetic Retinopathy - diagnosis ; Diabetic Retinopathy - drug therapy ; Dose-Response Relationship, Drug ; Female ; Follow-Up Studies ; Humans ; Intravitreal Injections ; Macula Lutea - pathology ; Macular Edema - diagnosis ; Macular Edema - drug therapy ; Macular Edema - etiology ; Male ; Microscopy, Acoustic ; Middle Aged ; Ranibizumab - administration & dosage ; Retrospective Studies ; Time Factors ; Tomography, Optical Coherence ; Treatment Outcome ; Vascular Endothelial Growth Factor A - antagonists & inhibitors ; Visual Acuity
Is Part Of: Asia-Pacific journal of ophthalmology (Philadelphia, Pa.), 2019-05, Vol.8 (3), p.200
Description: To investigate long-term outcomes of pro re nata (PRN) treatment protocol of ranibizumab for diabetic macular edema (DME) adopted from the first month of therapy without 3 loading doses. Retrospective interventional study. We analyzed 180 eyes of 144 patients treated with ranibizumab for DME with a minimum follow-up of 1 year during December 2013 to December 2017. Data of all patients with treatment-naive center-involving DME who received at least 1 intravitreal injection of ranibizumab during the study period were drawn from a locally adapted electronic form for DME. The primary outcome measure was change in best-corrected visual acuity (BCVA) from baseline at 1-year follow-up, with intergroup comparisons in BCVA between eyes receiving 1, 2, and 3 injections in the first 3 months of treatment. The mean baseline BCVA was 0.47 ± 0.30 logMAR, which improved to 0.38 ± 0.3 logMAR ( = 0.003) at 3 months and stabilized at 0.35 ± 0.27 logMAR at 1 year ( = 0.46 vs BCVA at 3 months) and 0.34 ± 0.26 logMAR at 2 years of follow-up ( = 0.44 vs BCVA at 3 months). At 3 months, 24 eyes (13%) underwent 1 intravitreal injection, 52 eyes (29%) had 2 injections, and the majority (n = 104 eyes, 58%) had 3 injections on a monthly basis. During the first year, the group that received only 1 injection in the first 3 months also required fewer injections and fewer follow-up visits compared with those receiving 2 or 3 injections in the first 3 months. One-third of eyes with DME responded well to PRN treatment strategy from the first month without 3 loading doses of ranibizumab. Baseline visual acuity is the best predictor of vision at 1 and 2 years of follow-up.
Publisher: United States
Language: English
Identifier: ISSN: 2162-0989
EISSN: 2162-0989
DOI: 10.22608/apo.2018413
PMID: 31165603
Source: MEDLINE
Alma/SFX Local Collection
DOAJ Directory of Open Access Journals

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

Visual Outcomes Following Intravitreal Ranibizumab for Diabetic Macular Edema in a Pro Re Nata Protocol from Baseline: A Real-World Experience

Copyright 2019 Asia-Pacific Academy of Ophthalmology. ;ISSN: 2162-0989 ;EISSN: 2162-0989 ;DOI: 10.22608/apo.2018413 ;PMID: 31165603

Searching Remote Databases, Please Wait